

Exploring the Current and Emerging Treatment Landscape for Relapsed or Refractory Follicular Lymphoma: Pharmacist Implications (Recorded Podcast)

Selected References:

1. Freedman A, Jacobsen E. Follicular lymphoma: 2020 update on diagnosis and management. *Am J Hematol*. 2020;95(3):316-327.
2. Luminari S, Trotman J, Federico M. Advances in treatment of follicular lymphoma. *Cancer J*. 2020;26(3):231-240.
3. Casulo C, Barr PM. How I treat early-relapsing follicular lymphoma. *Blood*. 2019;133(14):1540-1547.
4. O’Nions J, Townsend W. The role of obinutuzumab in the management of follicular lymphoma. *Future Oncol*. 2019;15(31):3565-3578.
5. Cheson BD, Chua N, Mayer J, et al. Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. *J Clin Oncol*. 2018;36(22):2259-2266.
6. Flowers CR, Leonard JP, Fowler NH. Lenalidomide in follicular lymphoma. *Blood*. 2020;135(24):2133-2136.
7. Leonard JP, Trneny M, Izutsu K, et al. AUGMENT: A phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. *J Clin Oncol*. 2019;37(14):1188-1199.
8. Morschhauser F, Le Gouill S, Feugier P, et al. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. *Lancet Haematol*. 2019;6(8):e429-e437.
9. Dreyling M, Santoro A, Mollica L, et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. *J Clin Oncol*. 2018;35(35):3898-3905.
10. Narkhede M, Cheson BD. Copanlisib in the treatment of non-Hodgkin lymphoma. *Future Oncol*. 2020;16(26):1947-1955.
11. Patel K, Danilov AV, Pagel JM. Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma. *Blood*. 2019;134(19):1573-1577.
12. Flinn IW, Miller CB, Ardeshtna KM, et al. DYNAMO: A phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. *J Clin Oncol*. 2019;37(11):912-922.
13. Barrientos JC. Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential. *Oncotargets Ther*. 2016;9:2945-2953.
14. Gopal AK, Kahl BS, de Vos S, et al. PI3K δ inhibition by idelalisib in patients with relapsed indolent lymphoma. *N Engl J Med*. 2014;370(11):1008-1018.
15. Morschhauser F, Tilly H, Chaidos A, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. *Lancet Oncol*. 2020;21(11):1433-1442.
16. Levin A, Shah NN. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas. *Am J Hematol*. 2019;94(S1):S18-S23.